Evidence map›Paper›PMID 26552452›Full record

ReviewThe Korean journal of internal medicine2015

Guidelines for the management of myeloproliferative neoplasms.

Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Korean journal of internal medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Interferons in the treatment of myeloproliferative neoplasms.Therapeutic advances in hematology · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chul Won ChoiDivision of Oncology-Hematology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
Soo-Mee BangDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Seongsoo JangDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Chul Won JungDivision of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hee-Jin KimDepartment of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ho Young KimDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Soo-Jeong KimDepartment of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Yeo-Kyeoung KimDivision of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Jinny ParkDivision of Hematology-Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Jong-Ho WonDivision of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as 'Philadelphia-negative classical myeloproliferative neoplasms (MPNs).' The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate- to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea.

Indexed as

Antineoplastic AgentsAsian PeopleHumansJanus Kinase 2Molecular Targeted TherapyMutationMyeloproliferative DisordersProtein Kinase InhibitorsRepublic of KoreaRisk FactorsSignal TransductionTreatment OutcomeAntineoplastic AgentsJAK2 protein, humanJanus Kinase 2Protein Kinase InhibitorsPolycythemia veraPractice guidelinePrimary myelofibrosisThrombocythemia, essential

Identifiers

PMID26552452
PMCPMC4642006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.